Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary By: Benzinga via Benzinga August 10, 2022 at 18:23 PM EDT Bristol Myers Squibb (NYSE: BMY) and 2seventy bio (NASDAQ: TSVT) announced positive topline results from KarMMa-3, a Phase 3 study ... Read More >> Related Stocks: 2seventy bio, Inc. - Common Stock Bridgebio Pharma Inc Bristol-Myers Squibb Lexaria Bioscience Corp Lianbio ADR Rani Therapeutics Holdings Inc Cl A Reshape Lifesciences Inc Tracon Pharmaceuticals Inc Vyne Therapeutics Inc